Interleukin Genetics Inc (ILI) financial statements (2022 and earlier)

Company profile

Business Address 135 BEAVER ST
WATHAM, MA 02452
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,6574,70611,4677,5421,225
Cash and cash equivalents2,6574,70611,4677,5421,225
Receivables1068638948
Inventory, net of allowances, customer advances and progress billings73125172190158
Inventory73125172190158
Prepaid expense435779505676
Prepaid expense and other current assets418
Other undisclosed current assets   535553
Total current assets:3,2715,69612,1818,9532,402
Noncurrent Assets
Property, plant and equipment511644774845127
Intangible assets, net (including goodwill)2559196290399
Intangible assets, net (excluding goodwill)2559196290399
Other noncurrent assets289311738
Prepaid expense and other noncurrent assets38
Total noncurrent assets:5657961,0861,172564
TOTAL ASSETS:3,8366,49213,26710,1252,966
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7449068571,088645
Accounts payable506408514835479
Accrued liabilities238498343253166
Debt2,3051,333   
Deferred revenue and credits2,5033,2393,1543,7831,628
Total current liabilities:5,5515,4784,0124,8722,273
Noncurrent Liabilities
Long-term debt and lease obligation1,1303,4754,739 14,316
Long-term debt, excluding current maturities1,1303,4754,739 14,316
Total noncurrent liabilities:1,1303,4754,739 14,316
Total liabilities:6,6818,9538,7504,87216,589
Stockholders' equity
Stockholders' equity attributable to parent(2,846)(2,461)4,5175,253(13,624)
Preferred stock    6
Common stock22917317312237
Additional paid in capital133,327126,354125,434119,88594,031
Accumulated deficit(136,402)(128,988)(121,090)(114,755)(107,697)
Total stockholders' equity:(2,846)(2,461)4,5175,253(13,624)
TOTAL LIABILITIES AND EQUITY:3,8366,49213,26710,1252,966

Income statement (P&L) ($ in thousands)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues2,5131,4411,8102,4302,236
Revenue, net1,0321,1561,6412,1692,155
Cost of revenue(1,602)(1,414)(1,435)(1,632)(1,329)
Gross profit:91127375797908
Operating expenses(7,585)(7,315)(6,704)(7,396)(5,578)
Operating loss:(6,674)(7,289)(6,329)(6,599)(4,670)
Nonoperating expense(741)(609)(6)(459)(450)
Investment income, nonoperating 0574
Interest and debt expense(741)(610)(11)(472)(454)
Other undisclosed income from continuing operations before equity method investments, income taxes74161011472454
Loss from continuing operations before income taxes:(7,414)(7,898)(6,336)(7,058)(5,120)
Income tax expense    (428)
Net loss:(7,414)(7,898)(6,336)(7,058)(5,548)
Other undisclosed net income attributable to parent    428
Net loss available to common stockholders, diluted:(7,414)(7,898)(6,336)(7,058)(5,120)

Comprehensive Income ($ in thousands)

12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(7,414)(7,898)(6,336)(7,058)(5,548)
Comprehensive loss, net of tax, attributable to parent:(7,414)(7,898)(6,336)(7,058)(5,548)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: